{"id":526573,"date":"2021-08-11T08:08:14","date_gmt":"2021-08-11T12:08:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/"},"modified":"2021-08-11T08:08:14","modified_gmt":"2021-08-11T12:08:14","slug":"vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/","title":{"rendered":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Live<\/em><br \/>\n        <em> video<\/em><br \/>\n        <em> webcast with <\/em><br \/>\n        <em>David Baker, President and CEO of <\/em><br \/>\n        <em>Vallon<\/em><br \/>\n        <em>,<\/em><br \/>\n        <em>on <\/em><br \/>\n        <em>Wednesday<\/em><br \/>\n        <em>, <\/em><br \/>\n        <em>August<\/em><br \/>\n        <em>18<\/em><br \/>\n        <sup><br \/>\n          <em>th<\/em><br \/>\n        <\/sup><br \/>\n        <em>12<\/em><br \/>\n        <em>:<\/em><br \/>\n        <em>30<\/em><br \/>\n        <em> PM<\/em><br \/>\n        <em> ET<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>PHILADELPHIA, PA, Aug.  11, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (\u201cVallon\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mXKt1sphbJPrc9v1ZPplv9qBQJ37TrBBJxis8kbQpz5lF7Rt-a92tRDKG_hUlGY08K3H8F1_XOnhKdZYkV4Cnc9SFu8AR2wRZLcY0FBIax1WSmFWXg7oU7DeR5Pqt4jcnNlDEw4vBxj8e_yi7tOqda_KTa88BpTZYbluvNiWwos=\" rel=\"nofollow noopener\" target=\"_blank\">David Baker, President &amp; Chief Executive Officer<\/a> of Vallon will present at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W-n2-HN_dv6zozE7Z5F2t_LVHDpsIHmAVOAmzhLAaOSTRHp6BYTXBcxSMsUzvXsM543NTUhsfeH4Ww_beau5tW5hpMVxFyIcsa9oPL83DvE=\" rel=\"nofollow noopener\" target=\"_blank\">Q3 Virtual Investor Summit<\/a> on Wednesday, August 18, 2021 at 12:30 PM ET.<\/p>\n<p align=\"justify\">In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4bT7-xPUT2dtUIoUN-y-gl-r_lkPUztGCafW7cqEaaBBYoHUvWKTh7Ir53qMgj7zaT-MqH-mU137tFR0gxEM03u7B4eBsVmXhfQrO6PwEs4=\" rel=\"nofollow noopener\" target=\"_blank\">conference website<\/a>.<\/p>\n<p align=\"justify\">A live <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kOefw7dADT7XF1GLiNE4i4b0N_RJrH7BqVpGZLEXzqciY0BTVLqe1b32w2QjMs0wB0cuoUjNvz_c_IYs4vV88X8pBR5RA-ZWPzn-WB1qb54KKfECE16Hbemr02LZ15vH\" rel=\"nofollow noopener\" target=\"_blank\">video webcast<\/a> of the presentation will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ad3B8-43UebjPEGiWT5W1CPjLKELhSqmNfd_OuP18Sg4-zwxM7G8kAdsysDsT4PPpW_pxBLdxXnYYaH7jZzaEVHHzwNrMuWjcT731gyn2ts=\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a> page in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ioOFGF3Kplr598KK37e6RrNVVpFxFD4xJQabBhtJBYVJRrjKDs0UtmugCofGiWfO6RDllxsw8iqwj3Sa1QRnzaZObiSQJDViKZH2FoaBDcw=\" rel=\"nofollow noopener\" target=\"_blank\">Investors<\/a> section of the Company\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-421dDkNyX1owyh5SKoNi_QojZK99N6P1ip-XtHE1xDJx7xh5rKQ4BrgU8AqM3k8POM9WTdFI_FCJCWnjNvhloO5kzOG6f_rgfQ2u0eOlBo=\" rel=\"nofollow noopener\" target=\"_blank\">www.vallon-pharma.com<\/a>) and will be archived for 90 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Vallon<\/strong><br \/>\n        <strong> Pharmaceuticals<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong> Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company\u2019s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.<\/p>\n<p align=\"justify\">For more information about the company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-421dDkNyX1owyh5SKoNi_QojZK99N6P1ip-XtHE1xDOZZnFkb8VB6svAAIGGipaAYzCAmPRxi5K88U2t2dAHWO-P-zA5qZBMAG3uCZcIV4=\" rel=\"nofollow noopener\" target=\"_blank\">www.vallon-pharma.com<\/a> or connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x9UsR-INxGQRmmiRtH1vMZVgRAdpOzrtb9emyOohBOYIHlumW-1SnLTlq_X_qXjv7x9X4sNUAut5hb7rqB9RPa7nu_-PxZchKYvE2X_FE-jfcZprcGheWn9-78Xq0yi1\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x-a12ihhP805mIPWPQpsKJ2vIBNDPyGYIW6r20P8X-EEWsUgZlm-Nai7s6jH0qMkRW26YXGrSVXtIcDb_Bfs6g==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>. <\/p>\n<p align=\"justify\">References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.<\/p>\n<p align=\"justify\">\n        <strong>Investor <\/strong><br \/>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(833) 475-8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u3LJTAcZCRIZM_lJTRN5eeroN8VTKfIMEmyL_gUITx06_e1C2EfGos4D_MI3s7qDcZo1D7yDMXu05233Qboytg==\" rel=\"nofollow noopener\" target=\"_blank\">vallon@jtcir.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTRjNGVjOGMtOWRiNy00ZWNlLTlmYWEtNDkzN2RhZWZjMGU2LTUwMDA3NTQ4OA==\/tiny\/Vallon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (\u201cVallon\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President &amp; Chief Executive Officer of Vallon will present at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526573","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (\u201cVallon\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President &amp; Chief Executive Officer of Vallon will present at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are &hellip; Continue reading &quot;Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T12:08:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit\",\"datePublished\":\"2021-08-11T12:08:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/\",\"name\":\"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\",\"datePublished\":\"2021-08-11T12:08:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/","og_locale":"en_US","og_type":"article","og_title":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk","og_description":"Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (\u201cVallon\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President &amp; Chief Executive Officer of Vallon will present at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are &hellip; Continue reading \"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T12:08:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit","datePublished":"2021-08-11T12:08:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/","name":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==","datePublished":"2021-08-11T12:08:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTQ2MCM0MzQ4NTQzIzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vallon-pharmaceuticals-to-present-at-the-q3-virtual-investor-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526573"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526573\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}